Rockwell Medical, Inc., announced today that the U.S. Food & Drug Administration (FDA) has approved its drug Triferic for commercial sale as an iron replacement product to maintain hemoglobin in adult patients with hemodialysis dependent chronic kidney disease.

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the Company has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin.

The FDA has granted orphan drug designation to a medication to prevent failure of a transplanted kidney immediately after transplantation.

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today the results of a Phase IIa study of oral laquinimod designed to assess safety, tolerability and clinical efficacy in patients with active lupus nephritis, one of the most serious manifestations of systemic lupus erythematosus (SLE or lupus) that can lead to chronic kidney failure.

Affymax, Inc. and Takeda Pharmaceutical Company Limited today have decided to voluntarily recall all lots of OMONTYS® (peginesatide) Injection to the user level as a result of new post-marketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life threatening or fatal.

The U.S. Department of Health and Human Services (HHS) is increasing awareness about a health plan for uninsured Americans with pre-existing conditions created by the Affordable Care Act.

Nearly 26 million Americans have diabetes, and another 79 million have prediabetes. That's about 30 percent of all Americans with a diabetes problem.